Media stories about Endocyte (NASDAQ:ECYT) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Endocyte earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.0469758372406 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

ECYT has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a research report on Friday, May 19th. Cowen and Company lowered shares of Endocyte from an “outperform” rating to a “market perform” rating in a research report on Friday, June 2nd. Wedbush lowered shares of Endocyte from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $8.00 to $2.00 in a research report on Monday, June 5th. Finally, ValuEngine lowered shares of Endocyte from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 3rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $3.58.

Endocyte (ECYT) traded down 0.72% during mid-day trading on Thursday, reaching $1.37. 423,977 shares of the company traded hands. Endocyte has a 52 week low of $1.17 and a 52 week high of $3.49. The stock’s 50 day moving average price is $1.38 and its 200 day moving average price is $1.93. The firm’s market capitalization is $58.33 million.

Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.03. Endocyte had a negative return on equity of 32.68% and a negative net margin of 61,437.14%. The company had revenue of $0.01 million for the quarter. During the same quarter in the previous year, the business posted ($0.25) earnings per share. Equities analysts forecast that Endocyte will post ($0.93) EPS for the current year.

WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at

About Endocyte

Insider Buying and Selling by Quarter for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.